March 28, 2023 06:47 AM EDTUpdated 07:02 AM

Esperion sues Daiichi Sankyo, demanding payment of $300M milestone for cardio drug

Drew Armstrong

Executive Editor

Kyle LaHucik

Senior Reporter

Esperion is suing its business partner Daiichi Sankyo, saying the Japanese drugmaker is improperly refusing to pay a $300 million milestone that the biotech company …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Esperion sues Daiichi Sankyo, demanding payment of $300M milestone for cardio drug

Drew Armstrong

Executive Editor

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Es­pe­ri­on sues Dai­ichi Sankyo, de­mand­ing pay­ment of $300M mile­stone for car­dio drug

Executive Editor

Senior Reporter

Sign up to read this article for free.

Esperion sues Daiichi Sankyo, demanding payment of $300M milestone for cardio drug